On July 2, HCA Healthcare rose 3.04% in regular trading, trading at $413.4/share, with turnover of $119 million. The move was driven by the publication of a landmark CRISPR gene-editing therapy study in the New England Journal of Medicine, in which HCA participated.

The study evaluated CRISPR-based gene therapy in children aged 5 to 11 with severe sickle cell disease and transfusion-dependent beta-thalassemia. Results showed all 8 beta-thalassemia patients achieved at least 12 months of transfusion independence, and all 8 sickle cell disease patients experienced no severe vaso-occlusive crises over at least 12 months. HCA is expanding access to this therapy through its Sarah Cannon Transplant and Cellular Therapy Network.

Within the Health Care Facilities sector, the broader group showed strength. Among individual stocks, Tenet Healthcare up 5.81%, Universal Health up 4.26%, Encompass Health Corporation up 3.07%, Acadia Healthcare up 2.75%, Nutex Health Inc up 1.2%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)